158 related articles for article (PubMed ID: 12651630)
21. The roles of ribosomal protein S19 C-terminus in a shortened neutrophil lifespan through delta lactoferrin.
Nishiura H; Yamanegi K; Kawabe M; Kato-Kogoe N; Yamada N; Nakasho K
Immunobiology; 2015 Sep; 220(9):1085-92. PubMed ID: 26003841
[TBL] [Abstract][Full Text] [Related]
22. Apoptotic cells of an epithelial cell line, AsPC-1, release monocyte chemotactic S19 ribosomal protein dimer.
Nishimura T; Horino K; Nishiura H; Shibuya Y; Hiraoka T; Tanase S; Yamamoto T
J Biochem; 2001 Mar; 129(3):445-54. PubMed ID: 11226885
[TBL] [Abstract][Full Text] [Related]
23. RP S19 C-terminal peptide trimer acts as a C5a receptor antagonist.
Nishiura H; Kawakami T; Kawabe M; Kato-Kogoe N; Yamada N; Nakasho K; Yamanegi K
Biochem Biophys Rep; 2016 Sep; 7():70-76. PubMed ID: 28955891
[TBL] [Abstract][Full Text] [Related]
24. Involvement of cross-linked ribosomal protein S19 oligomers and C5a receptor in definitive erythropoiesis.
Chen J; Zhao R; Semba U; Oda M; Suzuki T; Toba K; Hattori S; Okada S; Yamamoto T
Exp Mol Pathol; 2013 Dec; 95(3):364-75. PubMed ID: 24184702
[TBL] [Abstract][Full Text] [Related]
25. Pivotal Advance: Interconversion between pure chemotactic ligands and chemoattractant/secretagogue ligands of neutrophil C5a receptor by a single amino acid substitution.
Jia N; Semba U; Nishiura H; Kuniyasu A; Nsiama TK; Nishino N; Yamamoto T
J Leukoc Biol; 2010 Jun; 87(6):965-75. PubMed ID: 20089669
[TBL] [Abstract][Full Text] [Related]
26. Erythroblast differentiation at spleen in Q137E mutant ribosomal protein S19 gene knock-in C57BL/6J mice.
Yamanegi K; Yamada N; Nakasho K; Nishiura H
Immunobiology; 2018 Jan; 223(1):118-124. PubMed ID: 29017823
[TBL] [Abstract][Full Text] [Related]
27. Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.
Zhang X; Boyar W; Galakatos N; Gonnella NC
Protein Sci; 1997 Jan; 6(1):65-72. PubMed ID: 9007977
[TBL] [Abstract][Full Text] [Related]
28. The chemotactic receptor for human C5a anaphylatoxin.
Gerard NP; Gerard C
Nature; 1991 Feb; 349(6310):614-7. PubMed ID: 1847994
[TBL] [Abstract][Full Text] [Related]
29. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo.
Pellas TC; Boyar W; van Oostrum J; Wasvary J; Fryer LR; Pastor G; Sills M; Braunwalder A; Yarwood DR; Kramer R; Kimble E; Hadala J; Haston W; Moreira-Ludewig R; Uziel-Fusi S; Peters P; Bill K; Wennogle LP
J Immunol; 1998 Jun; 160(11):5616-21. PubMed ID: 9605167
[TBL] [Abstract][Full Text] [Related]
30. Antagonistic peptides against human anaphylatoxin C5a.
Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
[TBL] [Abstract][Full Text] [Related]
31. Signaling by hemolytically inactive C5b67, an agonist of polymorphonuclear leukocytes.
Wang C; Gerard NP; Nicholson-Weller A
J Immunol; 1996 Jan; 156(2):786-92. PubMed ID: 8543834
[TBL] [Abstract][Full Text] [Related]
32. Modulation of monocyte chemotactic function in inflammatory lesions. Role of inflammatory mediators.
Katona IM; Ohura K; Allen JB; Wahl LM; Chenoweth DE; Wahl SM
J Immunol; 1991 Jan; 146(2):708-14. PubMed ID: 1898961
[TBL] [Abstract][Full Text] [Related]
33. The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization.
Bock D; Martin U; Gärtner S; Rheinheimer C; Raffetseder U; Arseniev L; Barker MD; Monk PN; Bautsch W; Köhl J; Klos A
Eur J Immunol; 1997 Jun; 27(6):1522-9. PubMed ID: 9209506
[TBL] [Abstract][Full Text] [Related]
34. Role of ribosomal protein S19-like plasma protein in blood coagulum resorption.
Ota Y; Chen J; Shin M; Nishiura H; Tokita K; Shinohara M; Yamamoto T
Exp Mol Pathol; 2011 Feb; 90(1):19-28. PubMed ID: 21112324
[TBL] [Abstract][Full Text] [Related]
35. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
36. Structure-function relationships of human C5a and C5aR.
Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Padgaonkar VA; Younkin EM; Guo RF; Weber CH; Zuiderweg ER; Zetoune FS; Ward PA
J Immunol; 2003 Jun; 170(12):6115-24. PubMed ID: 12794141
[TBL] [Abstract][Full Text] [Related]
37. Biologic activity of synthetic analogues of C5a anaphylatoxin.
Ember JA; Sanderson SD; Taylor SM; Kawahara M; Hugli TE
J Immunol; 1992 May; 148(10):3165-73. PubMed ID: 1578141
[TBL] [Abstract][Full Text] [Related]
38. Receptor activation by human C5a des Arg74 but not intact C5a is dependent on an interaction between Glu199 of the receptor and Lys68 of the ligand.
Crass T; Bautsch W; Cain SA; Pease JE; Monk PN
Biochemistry; 1999 Jul; 38(30):9712-7. PubMed ID: 10423250
[TBL] [Abstract][Full Text] [Related]
39. [A novel monocyte chemotactic factor that connects innate immunity and acquired immunity].
Yamamoto T
Rinsho Byori; 2000 Jul; 48(7):634-8. PubMed ID: 11051789
[TBL] [Abstract][Full Text] [Related]
40. Development of C5a receptor antagonists. Differential loss of functional responses.
Konteatis ZD; Siciliano SJ; Van Riper G; Molineaux CJ; Pandya S; Fischer P; Rosen H; Mumford RA; Springer MS
J Immunol; 1994 Nov; 153(9):4200-5. PubMed ID: 7930622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
